Journal of Medicinal Chemistry · 2019 · 48 citations · 56 references
PharmacyMedicinal ChemistryMolecular BiologyDrug DesignDrug DiscoveryMolecular Cell BiologyMolecular DockingPotency OptimizationE3 Ubiquitin Ligase Substrate RecognitionLead Compound OptimizationLigase InhibitorsMolecular Docking AnalysisProtein-protein Interaction Inhibitor DesignProtein-protein Interaction Inhibitor DiscoveryTherapeutic Target IdentificationThermal Shift Assays
= 15 nM). Next, using protein and cellular thermal shift assays, coimmunoprecipitation, molecular docking, and site-specific mutation experiments, we further proved that DC-2 specifically inhibited the interaction of UBE2M and DCN1 at molecule and cellular levels, resulting in the decrease of cullin3 neddylation and accumulation of its substrate, NRF2. Our findings indicate that DC-2 may serve as a novel lead compound for specific derivatives targeting DCN1-UBE2M interaction.
56
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Daniel Martinez Molina, Rozbeh Jafari, Marina Ignatushchenko et al. · Science · 2013 · 2.2K citations
Medicine, Oncology, Pharmacology +17
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Teresa A. Soucy, Peter G. Smith, Michael A. Milhollen et al. · Nature · 2009 · 2K citations